Intercept Pharmaceuticals Inc

-0.05 (-0.37%)
Products, Regulatory

Intercept Announces New Clinical Trial And Real-World Outcomes Data For Ocaliva In Pbc

Published: 06/03/2022 11:48 GMT
Intercept Pharmaceuticals Inc (ICPT) - Intercept Announces New Clinical Trial and Real-world Outcomes Data for Ocaliva in Pbc.
Intercept Pharmaceuticals- Cobalt Study in Advanced Pbc Did Not Demonstrate a Statistically Significant Difference in Clinical Endpoints Between Ocaliva, Placebo.
Intercept Pharmaceuticals- Heroes-us Real-world Analysis Showed Statistically Significant Improvement in Event-free Survival in Patients Receiving Ocaliva for Pbc.
Intercept Pharmaceuticals Inc- Plans to Include Data in an Evidence Package That Will Be Submitted to U.S. FDA in 2h 2022.